Regulation of the p53 tumor suppressor pathway: The problems and promises of studying Mdm2's E3 ligase function

Critical Reviews in Eukaryotic Gene Expression

Volumn 20, Issue 1, 2010, Pages 77-86

  Clegg, Hilary V ^a   Zhang, Yanping ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Hdm2; Knock in mouse model; Mdm2; P53; RING domain; Ubiquitin

Indexed keywords

PROTEIN MDM2; PROTEIN P53; UBIQUITIN PROTEIN LIGASE E3;

CANCER THERAPY; GENE CONTROL; GENE FUNCTION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; TUMOR SUPPRESSOR GENE; UBIQUITINATION;

EID: 77953900594     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukarGeneExpr.v20.i1.60     Document Type: Review

References (48)

1. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237-1245
2. Chen C-Y, Oliner JD, Zhan Q, Fornace AJ, Vogelstein B, Kastan M. Interaction between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci U S A. 1994;91:2684-2688 (Pubitemid 24139412)
3. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer. 2006 Dec;6(12):909-923
4. Luna RM, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2- defi cient mice by deletion of p53. Nature. 1995;378:203-206
5. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature.1995;378:206-208
6. Itahana K, Mao H, Jin A, Itahana Y, Clegg HV, Lindstrom MS, Bhat KP, Godfrey VL,Evan GI, Zhang Y. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell. 2007 Oct;12(4):355-366
7. Wade M, Wahl GM. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res. 2009 Jan;7(1):1-11.
8. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature. 1993;362:857-860
9. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296-299
10. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997;420:25-27
11. Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387:299-303.
12. Chen J, Lin J, Levine AJ. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol Med. 1995;1:142-152
13. Thut CJ, Goodrich JA, Tjian R. Repression of p53-mediated transcription by MDM2, a dual mechanism. Genes Dev. 1997;11:1974-1986
14. Christophorou MA, Martin-Zanca D, Soucek L, Lawlor ER, Brown-Swigart L, Verschuren EW, Evan GI. Temporal dissection of p53 function in vitro and in vivo. Nat Genet.2005 Jul;37(7):718-726
15. Clegg HV, Itahana K, Zhang Y. Unlocking the Mdm2-p53 loop: ubiquitin is the key. Cell Cycle. 2008 Feb 1;7(3):287-292
16. Tanimura S, Ohtsuka S, Mitsui K, Shirouzu K, Yoshimura A, Ohtsubo M. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett. 1999 Mar 19;447(1):5-9.
17. Sharp DA, Kratowicz SA, Sank MJ, George DL. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J Biol Chem. 1999;274:38189-38196
18. Jackson MW, Berberich SJ. MdmX protects p53 from Mdm2-mediated degradation. Mol Cell Biol. 2000;20:1001-1007
19. Stad R, Ramos YFM, Litle N, Grivell S, Attema J, van der Eb AJ, Jochmsen AG. Hdmx stabilizes Mdm2 and p53. J Biol Chem. 2000;275:28039-28044
20. Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, Lozano G. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet. 2001 Sep;29(1):92-95
21. Linares LK, Hengstermann A, Ciechanover A, Muller S, Scheffner M. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12009-12014
22. Kawai H, Lopez-Pajares V, Kim MM, Wiederschain D, Yuan ZM. RING domainmediated interaction is a requirement for MDM2s E3 ligase activity. Cancer Res. 2007 Jul 1;67(13):6026-6030
23. Uldrijan S, Pannekoek WJ, Vousden KH. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J. 2007 Jan 10;26(1):102-112
24. Poyurovsky MV, Priest C, Kentsis A, Borden KL, Pan ZQ, Pavletich N, Prives C. The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J. 2007 Dec 14;26(1):90-101.
25. Balagurumoorthy P, Sakamoto H, Lewis MS, Zambrano N, Clore GM, Gronenborn AM, Appella E, Harrington RE. Four p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA. Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8591-8595
26. Wang Y, Schwedes JF, Parks D, Mann K, Tegtmeyer P. Interaction of p53 with its consensus DNA-binding site. Mol Cell Biol. 1995 Apr;15(4):2157-2165
27. Le Cam L, Linares LK, Paul C, Julien E, Lacroix M, Hatchi E, Triboulet R, Bossis G, Shmueli A, Rodriguez MS, Coux O, Sardet C. E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell. 2006 Nov 17;127(4):775-788
28. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science. 2003 Dec 12;302(5652):1972-1975
29. Marchenko ND, Wolff S, Erster S, Becker K, Moll UM. Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J. 2007 Feb 21;26(4):923-934
30. Wang P, Reed M, Wang Y, Mayr G, Stenger JE, Anderson ME, Schwedes JF, Tegtmeyer P. p53 domains: structure, oligomerization, and transformation. Mol Cell Biol. 1994 Aug; 14(8):5182-5191
31. Nakamura S, Roth JA, Mukhopadhyay T. Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2- dependent protein degradation and ubiquitination.Mol Cell Biol. 2000;20:9391-9398
32. Carter S, Bischof O, Dejean A, Vousden KH. C-terminal modifi cations regulate MDM2 dissociation and nuclear export of p53. Nat Cell Biol. 2007 Apr;9(4):428-435
33. Brooks CL, Li M, Gu W. Mechanistic studies of MDM2-mediated ubiquitination in p53 regulation. J Biol Chem. 2007 Aug 3; 282(31):22804-22815
34. Minsky N, Oren M. The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. Mol Cell. 2004 Nov 19;16(4):631-639
35. Francoz S, Froment P, Bogaerts S, De Clercq S, Maetens M, Doumont G, Bellefroid E, Marine JC. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3232-3237
36. Toledo F, Krummel KA, Lee CJ, Liu CW, Rodewald LW, Tang M, Wahl GM. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 defi ciency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell. 2006 Apr;9(4):273-285
37. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. Mdm2 is a RING fi ngerdependent ubiquitin protein ligase for itself and p53. J Biol Chem. 2000;275:8945-8951
38. Honda R, Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING fi nger domain of the ligase. Oncogene. 2000;19:1473-1476
39. Linke K, Mace PD, Smith CA, Vaux DL, Silke J, Day CL. Structure of the MDM2/ MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ. 2008 May;15(5):841-848
40. Okamoto K, Taya Y, Nakagama H. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase. FEBS Lett. 2009 Sep 3;583(17): 2710-2714
41. Linares LK, Kiernan R, Triboulet R, Chable- Bessia C, Latreille D, Cuvier O, Lacroix M, Le Cam L, Coux O, Benkirane M. Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat Cell Biol. 2007 Mar;9(3):331-338
42. Jin Y, Zeng SX, Lee H, Lu H. MDM2 mediates p300/CREB-binding protein associated factor ubiquitination and degradation. J Biol Chem. 2004 May 7;279(19):20035-20043
43. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med. 2007 Jan;13(1): 23-31.
44. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by smallmolecule antagonists of MDM2. Science. 2004 Feb 6;303(5659):844-848
45. Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, Nikolovska-Coleska Z, Ding K, Wang G, Chen J, Bernard D, Zhang J, Lu Y, Gu Q, Shah RB, Pienta KJ, Ling X, Kang S, Guo M, Sun Y, Yang D, Wang S. Temporal activation of p53 by a specifi c MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3933-3938
46. Auger KR, Copeland RA, Lai Z. Quantitative assays of Mdm2 ubiquitin ligase activity and other ubiquitin-utilizing enzymes for inhibitor discovery. Methods Enzymol. 2005; 399:701-717
47. Lai Z, Yang T, Kim YB, Sielecki TM, Diamond MA, Strack P, Rolfe M, Caligiuri M, Benfi eld PA, Auger KR, Copeland RA. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc Natl Acad Sci U S A. 2002 Nov 12; 99(23):14734-14739
48. Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov IV, Safiran YJ, Oberoi P, Kenten JH, Phillips AC, Weissman AM, Vousden KH. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell. 2005 Jun;7(6):547-559